

AGENUS INC  
Form 4  
July 03, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**JORDAN WADIIH**

(Last) (First) (Middle)

**ANTIGENICS INC., 149 FIFTH  
AVE., SUITE 500**

(Street)

**NEW YORK, NY 10010**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol  
**AGENUS INC [agen]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**06/29/2017**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify  
below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------|
|                                       |                                         |                                                             | Code                                 | V Amount (D) Price                                                         |                                                                                                                    |                                                                      |                                                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
**(e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of<br>Derivative<br>Security | 2. Conversion<br>or Exercise | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any | 4. Transaction<br>Code | 5. Number of<br>Derivative<br>Securities | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount<br>Underlying Secur<br>(Instr. 3 and 4) |
|---------------------------------------|------------------------------|-----------------------------------------|-----------------------------------------|------------------------|------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------|
|---------------------------------------|------------------------------|-----------------------------------------|-----------------------------------------|------------------------|------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------|

# Edgar Filing: AGENUS INC - Form 4

| (Instr. 3)                          | Price of<br>Derivative<br>Security | (Month/Day/Year) | (Instr. 8) | Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4, and 5) | Code | V | (A) | (D) | Date Exercisable          | Expiration<br>Date | Title           | Am<br>Nun<br>Sha |
|-------------------------------------|------------------------------------|------------------|------------|------------------------------------------------------------|------|---|-----|-----|---------------------------|--------------------|-----------------|------------------|
| Deferred<br>Shares <sup>(1)</sup>   | \$ 3.583                           | 06/30/2017       | A          | 4,186.603                                                  |      |   |     |     | <sup>(1)</sup>            | <sup>(1)</sup>     | Common<br>Stock | 4,1              |
| Stock<br>Option,<br>Right to<br>buy | \$ 3.91                            | 06/29/2017       | A          | 50,000                                                     |      |   |     |     | 06/29/2018 <sup>(2)</sup> | 06/29/2027         | Common<br>Stock | 5                |
| Stock<br>Option,<br>Right to<br>buy | \$ 3.91                            | 06/29/2017       | A          | 2,500                                                      |      |   |     |     | 06/29/2018 <sup>(3)</sup> | 06/29/2027         | Common<br>Stock | 2                |

## Reporting Owners

| Reporting Owner Name / Address                                                      | Relationships |           |         |       |
|-------------------------------------------------------------------------------------|---------------|-----------|---------|-------|
|                                                                                     | Director      | 10% Owner | Officer | Other |
| JORDAN WADIIH<br>ANTIGENICS INC.<br>149 FIFTH AVE., SUITE 500<br>NEW YORK, NY 10010 | X             |           |         |       |

## Signatures

Christine M. Klaskin, by Power of Attorney  
Date 07/03/2017

<sup>\*\*</sup>Signature of Reporting Person      Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Acquired under the Agenus Inc. Director Deferred Compensation Plan, as amended. Deferred Shares represent an equal amount of the Company's common stock to be distributed under the terms of the plan, typically once the director ceases to serve as a director of the Company.

(2) Annual option award vesting 100% on the earlier of the one-year anniversary of the grant date or the date of the Company's 2018 annual shareholder meeting.

(3) Option vests 100% on the one-year anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.